Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AveXis

- PMLiVE

Novartis’ Egatan gains US approval for neglected tropical disease

US approval removes barrier to greater access

- PMLiVE

Novartis first to benefit from NICE advice on ‘patient preference’

Consultancy spin-off looking to expand services

Roche Basel Switzerland

Roche submits Kadcyla for FDA Real-Time review

Aims to extend use in breast cancer patients

- PMLiVE

CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL

Novartis agrees pricing deal with NHS England

- PMLiVE

Nerve centre gives Novartis edge in clinical trials

Algorithms predict potential delays

- PMLiVE

Novartis aims for 10 blockbuster launches by 2020

Includes new gene therapy Zolgensma

- PMLiVE

Immunomedics craters after FDA rejects breast cancer ADC

Regulator wants to see more data on manufacturing

Novartis Gehry Building

Novartis forges AI alliance with Oxford University

Part of Novartis drive to become 'data-driven' pharma company

Sanofi reception

FDA adcomm split on Sanofi’s type 1 diabetes drug

Concerns rose after Zynquista-treated patients showed an eight-fold increase in DKA

- PMLiVE

Evenity back on track with FDA panel blessing in osteoporosis

US drugs regulator first rejected the drug due to cardiovascular concerns

- PMLiVE

FDA expecting boom in cell and gene therapies

Pledges clampdown on developers working outside regulations

- PMLiVE

FDA moves into crisis mode as shutdown drags on

New drug appraisals already being affected

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links